eGenesis lands $14M convertible note from India's NATCO Pharma
What's the deal? eGenesis, a Cambridge, Massachusetts biotech developing transplantable organs through genome engineering, has raised $14 million via convertible promissory notes from India's NATCO PharmaDealroom has a profile for this one. Try Dealroom →. The infusion lifts NATCO's total stake to $22 million, following an $8 million preferred-stock investment in 2024.
How it's structured: The funding flows through two NATCO units — NATCO Pharma (Canada) Inc.Dealroom has a profile for this one. Try Dealroom → ($9.5 million) and NATCO Pharma South AfricaDealroom has a profile for this one. Try Dealroom → ($4.5 million).
What's the endgame? eGenesis uses its EGEN platform to edit pig genomes, tackling the molecular incompatibilities and viral risks that block cross-species transplants. It is running programs in kidney transplants, acute liver failure, and heart transplants to ease the global organ shortage.
Why now? The company performed the world's first porcine kidney transplant in a living patient in March 2024, authorised by the Food and Drug Administration, and has since transplanted two more patients. It remains a clinical-stage, pre-revenue firm.
The signal: At $14 million, the round lands in the 92nd percentile for convertible deals among US health startups — a sizeable cheque for a pre-revenue company. It also marks a deepening bet by a generic-drug maker on regenerative medicine and gene editing.
Read more: investywise.com
Image credit: USDAgov
